Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
RNN > SEC Filings for RNN > Form 8-K on 3-Mar-2014All Recent SEC Filings

Show all filings for REXAHN PHARMACEUTICALS, INC.

Form 8-K for REXAHN PHARMACEUTICALS, INC.


3-Mar-2014

Change in Directors or Principal Officers, Financial Statements and


Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of February 26, 2014, Rexahn Pharmaceuticals, Inc., a Delaware corporation (the "Company") appointed Mark P. Carthy to serve as a director of the Company until the 2014 annual meeting of stockholders and until his successor is duly elected and qualified.

Mr. Carthy is the Managing Partner of Orion Equity Partners, LLC, a healthcare venture capital management and advisory firm co-founded by Mr. Carthy in 2008. Prior to founding Orion, Mr. Carthy was a Venture Partner and General Partner at Oxford Bioscience Partners, an early stage venture capital firm that provides equity financing and management assistance to companies within the life sciences, technology, energy and healthcare sectors. From 1998 until 2000, Mr. Carthy served as the Biotechnology Portfolio Manager at Morningside Ventures where he focused on early stage private equity investments. Previously, he was Chief Business Officer of Cubist Pharmaceuticals and Senior Director of Business Development at Vertex Pharmaceuticals. Mr. Carthy served as a member of the board of the New England Venture Capital Association from 2006 until 2013 and was listed on the Forbes Midas List in 2009 as one of the leading venture capitalists. He received a Bachelor of Chemical Engineering from the University College Dublin, Ireland, a Master of Science in Chemical Engineering from the University of Missouri and a Master of Business Administration from the Harvard Graduate School of Business Administration.

Consistent with the Company's compensation policy for non-employee directors, Mr. Carthy will receive (i) a pro-rated annual retainer of $6,667 for his service on the Board of Directors of the Company (the "Board"), plus an additional $2,000 fee per in-person meeting of the Board and an additional $500 fee per telephonic meeting of the Board, and (ii) 20,000 options to purchase shares of the common stock of the Company.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Rexahn Pharmaceuticals, Inc. press release dated March 3, 2014, reporting the addition of Mark P. Carthy to its Board of Directors.


  Add RNN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for RNN - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.